PTC Therapeutics, Inc. (PTCT)

NMS – Цена в реальном времени. Валюта: USD

75.02

-1.83 (-2.38%)

При закрытии: May 12, 2026, 4:00 PM EDT

75.02

0.00 (0.00%)

После закрытия: May 12, 2026, 4:20 PM EDT

08.05.2026

PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.

08.05.2026

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

07.05.2026

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

07.05.2026

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.

07.05.2026

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback – WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.

06.05.2026

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.

04.05.2026

PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026 Tuesday, May 12 at 8:40 a.m.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

28.04.2026

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort.

17.04.2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee.

25.03.2026

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors.

PTC Therapeutics, Inc. (PTCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

PTC Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

PTC Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

Search stocks

PTC Therapeutics, Inc. (PTCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

PTC Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

PTC Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors